sccablog.org Report : Visit Site

Technical data of the sccablog.org

Geo IP provides you such as latitude, longitude and ISP (Internet Service Provider) etc. informations. Our GeoIP service found where is host sccablog.org. Currently, hosted in United States and its service provider is Unified Layer .

HTTP Header Analysis

HTTP Header information is a part of HTTP protocol that a user's browser sends to called nginx/1.14.0 containing the details of what the browser wants and will accept back from the web server.

DNS

HtmlToText

seattle cancer care alliance -- fred hutch seattle children's uw medicine better together. about diseases & treatment how to help find doctor make appointment contact scca blog « older posts notes and news from ash 2017 by pam mandel | published: january 1, 2018 it was snowing in atlanta the day the seattle cancer care alliance (scca) team of doctors, researchers and fellows flew out to attend the annual meeting of the american society of hematology. travel delays aside, it was an exciting four days of recognition for the work scca has done in hematology – and an excellent opportunity to share research with others in the field. here are a few highlights from ash 2017. after 22 years as a member, dr. stephanie lee , a hematologist at scca was inducted as the new vice president of ash. lee will be the first fred hutch faculty member to serve on the ash executive committee since hutch bone marrow transplant pioneer and nobel laureate dr. e. donnall thomas served as president in 1988. “we are thrilled by dr. lee’s accomplishment and the role she will have in leading our field,” said dr. gary gilliland, president and director of fred hutch. “it is particularly notable that she is the first hutch member to be elected president of ash since don thomas.” dr. lee’s research is aimed at improving the lives of transplant recipients. read the whole story here. read the whole story here . the motley fool takes an investor perspective on what new drugs for non-hodgkin lymphoma (nhl) and multiple myeloma patients mean, but they’re also clear about benefits for patients. the american society of hematology (ash) annual meeting this past weekend was chock-full of excitement, including an unexpected snowstorm in atlanta and a slew of game-changing non-hodgkin lymphoma (nhl) and multiple myeloma trial results for chimeric antigen receptor t-cell therapies (car-t). these car-t trial results suggest we’re fast approaching a major shift in how we battle blood cancer, so let’s look at the latest data. read the full story here . our caregiver support team is fully aware of how taxing the role of caregiver can be. at scca, we continually strive to support everyone involved in a patient’s treatment. this year, fred hutch researchers presented the results of a study on caregiver quality of life. being the caregiver of a loved one with a serious illness can be a tough job, both physically and emotionally. and as revealed by these quotes from anonymous caregivers in a new study, it’s a role that’s often under the radar despite its importance for patients’ well-being. read the full story here . twelve percent of adults with acute myeloid or acute lymphoblastic experience graft failure, according to a study presented at ash. but dr. fillippo milano , associate director of the cord blood transplant program at scca comments that there’s a lower rate of failure at scca. i was really surprised by the graft failure rate of 12% after both single and double umbilical cord transplants, which is much higher than what we usually see in our single-center experience. for instance, at our center in seattle, umbilical cord rejection is less than 5%. read the full story here . dr. oliver press embodied the advancement of hematology with his work to mentor those entering the field. ash recognized dr. press for his work by posthumously awarding him a 2017 mentor award. he mentored more than 70 individuals since the 1980s, including undergraduates, medical students, phd students, and postdoctoral fellows. his dedication to mentorship has been recognized with an award named in his honor, the oliver w. press distinguished mstp alumnus award, which acknowledges a graduate of the university of washington school of medicine’s medical scientist training program. he also received the department of medicine mentorship award from the university of washington. read the full story here . for those interested in learning, there’s a full review of all sessions presented at ash online at hematology 2017 . share this: facebook twitter email posted in events | tagged ash , ash2017 | comments closed a new option for high-risk multiple myeloma? by pam mandel | published: december 19, 2017 study of three-step treatment approach reopens question of donor bone marrow transplant after a diagnosis of high-risk multiple myeloma, seattle-area resident todd hirai participated in a clinical trial at the fred hutch bmt program at scca testing two different types of bone marrow transplant in succession followed by a cancer-suppressing drug. photo by bo jungmayer / fred hutch after a diagnosis of high-risk multiple myeloma, seattle-area resident todd hirai participated in a clinical trial at the fred hutch bmt program at seattle cancer care alliance testing two different types of bone marrow transplant in succession followed by a cancer-suppressing drug. six years ago, todd hirai learned why all the physical therapy he’d received for his baseball injury hadn’t eased his back pain. he hadn’t wrenched his back in the batting cage after all, said the scan glowing on his orthopedist’s computer screen. hirai saw the bright spots scattered across the mri, lighting up his bones like a nightmarish swarm of fireflies. it looked, explained the orthopedist, like cancer. as the seattle-area father of three tried to wrap his mind around this news, a medical team was waiting just outside the door to admit him into the hospital and start the process of trying to save his life from what was swiftly confirmed to be multiple myeloma . hirai soon learned that his cancer’s genetic abnormalities placed him in a high-risk category, one that is associated with an average of less than three years’ survival. after discussions with his doctors, hirai enrolled in a clinical trial through fred hutchinson cancer research center of a complex combination protocol, one that researchers believed might help patients like him. “it was my only real shot at survival at that point,” hirai said. after years of following up with hirai and his cohort on that small trial, a team of 12 fred hutch researchers published their promising results recently in the journal blood advances. they hope these findings will be a springboard to a more in-depth study of this approach. the team found that trial participants like hirai with newly diagnosed, high-risk multiple myeloma have a longer-than-expected average survival time after undergoing the trial’s three-part treatment sequence — two different types of bone marrow transplant in succession followed by a cancer-suppressing drug. while the trial was not designed to offer a definitive answer about the benefits of this approach, the results offer a useful new clue toward solving a long-standing controversy in the multiple myeloma field, said the investigators: namely, whether a transplant from a donor could be beneficial for patients with this disease and, if so, for which patients. dr. marco mielcarek was the trial’s lead investigator. photo by kris krüg for seattle cancer care alliance “our take-home message is that [this protocol] should probably be looked at in a larger, prospective and, ideally, randomized study — and that there might be some potential with this approach … for newly diagnosed patients with high-risk myeloma,” said the scca’s dr. marco mielcarek , the trial’s principal investigator. for such patients “we should keep an open mind and consider allogeneic [donor] transplants followed by some form of maintenance therapy,” he said. a multitude of medical advances over the past decade have resulted in big improvements in treatment for myeloma — but less so for the high-risk form. as research on this approach continues, these early findings will help inform treatment options that physicians in the fred hutch/university of washington cancer consortium can offer to newly diagnosed high-risk patients, the investigators said. “some people have said that it’s settled, whether there’s a role for any type of allogenei

URL analysis for sccablog.org

http://www.sccablog.org/2017/12/scca-heads-into-a-leadership-role-at-50th-annual-ash-meeting/?share=twitter
http://www.sccablog.org/tag/non-hodgkin-lymphoma/
http://www.sccablog.org/tag/lymphoma/
http://www.sccablog.org/tag/clinical-trials/
http://www.sccablog.org/2017/12/a-new-option-for-high-risk-multiple-myeloma/?share=facebook
http://www.sccablog.org/category/events/
http://www.sccablog.org/category/uncategorized/
http://www.sccablog.org/2017/12/car-t-cell-therapies-advance-the-possibilities-of-immunotherapy-at-scca/
http://www.sccablog.org/2017/09/prostate-cancer-survivor-scca-saved-my-life-twice/
http://www.sccablog.org/2017/09/new-genetic-study-for-metastatic-prostate-cancer/
http://www.sccablog.org/2017/10/scca-top-nurse-named-fellow-of-american-academy-of-nursing/
http://www.sccablog.org/2017/10/combating-breast-cancer-health-disparities-with-education-support/
http://www.sccablog.org/mainblog/wp-content/uploads/2017/12/marco-mielcarek.jpg
http://www.sccablog.org/tag/yescarta/
http://www.sccablog.org/tag/myelomas/

Whois Information

Whois is a protocol that is access to registering information. You can reach when the website was registered, when it will be expire, what is contact details of the site with the following informations. In a nutshell, it includes these informations;

WHOIS LIMIT EXCEEDED - SEE WWW.PIR.ORG/WHOIS FOR DETAILS

  REFERRER http://www.pir.org/

  REGISTRAR Public Interest Registry

SERVERS

  SERVER org.whois-servers.net

  ARGS sccablog.org

  PORT 43

  TYPE domain

  REGISTERED unknown

DOMAIN

  NAME sccablog.org

NSERVER

  NS2.BLUEHOST.COM 162.159.25.175

  NS1.BLUEHOST.COM 162.159.24.80

Mistakes

The following list shows you to spelling mistakes possible of the internet users for the website searched .